Clinical trial
A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Intravenous Monoclonal Antibody (mAb) After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis.
NCT05513950 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Intravenous Monoclonal Antibody (mAb) After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis.
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 25, 2023
- Completion date
- June 17, 2024
- Enrollment
- 52 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.